4DMedical (ASX:4DX) has shot up 4% approaching the final hour of trades as the company reveals its tech was recently presented to U.S. Congress.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
Through the trading day, the company hit value jumps as lofty as +14% too.
That presentation was conducted by the CEO of Philips North America, Jeff DiLulllo, with whom 4DX has a partnership around its lung-imaging tech, which it says produces a “four-dimensional” model of lungs in patients who are scanned.
(This makes no sense: It’s a three-dimensional model, but, whatever, don’t let that get in the way of a good pitch.)
DiLullo presented to the House of Reps’ Committee on Veterans’ Affairs and put it to congressional members that 4DX could ultimately assist in triaging veterans with lung conditions more efficiently in hospital settings.
At the same time, in the U.S., burn pit-related damages have recently received attention down under, given the increasing commonality of that type of VA claim.
This wasn’t explicitly outlined to Congress but has formed part of 4DX’s defence-facing strategies in recent years.
“Acknowledging the need for… less invasive ways to identify and diagnose lung disease, Philips, in concert with our partner, 4DMedical, innovated an FDA-cleared cardiopulmonary software that can transform standard CT imaging into a detailed four-dimensional image,” DiLullo said.
“This advanced technology allows VA clinicians to better assess pulmonary function and leads to faster diagnoses and less invasive procedures.”
If Congress’s VA committee members weren’t aware of 4DMedical, they are now – thus the somewhat moderate share-buying action.
At the same time, the Aussie biotech company also revealed it will be part of a trial with San Diego-based SMS Biotech using its lung imaging tech to assess lung health after treatment with novel stem cells.
In the background: An undisclosed third party also wants to use its imaging tech in a study of its own related to lung health.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please clickhere.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)